Metraipolis › archive › dc_2a3b451cf5bc

Adverse events of pexidartinib for the treatment of TGCT: a real-world disproportionality analysis using FDA Adverse Event Reporting System database — Europe PMC PMID:40900794

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40900794
DOI
10.3389/fonc.2025.1594585
License (as archived)
solo-consultazione
Archived
2026-11-10T12:58:06.700Z
SHA-256 of the archived text
95ffde38e04148604ecb2983c9437d10cb85e52e065b58579902ccd35da4ab0f
Stable URL of this page
https://metraipolis.com/documento/dc_2a3b451cf5bc

How to cite

Adverse events of pexidartinib for the treatment of TGCT: a real-world disproportionality analysis using FDA Adverse Event Reporting System database — Europe PMC PMID:40900794 — Europe PMC (en), https://europepmc.org/article/MED/40900794 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2a3b451cf5bc (Metraipolis archive dc_2a3b451cf5bc, sha256 95ffde38e04148604ecb2983c9437d10cb85e52e065b58579902ccd35da4ab0f)
BibTeX
@misc{dc2a3b451cf5bc,
  title = {Adverse events of pexidartinib for the treatment of TGCT: a real-world disproportionality analysis using FDA Adverse Event Reporting System database — Europe PMC PMID:40900794},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40900794},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2a3b451cf5bc; sha256 95ffde38e04148604ecb2983c9437d10cb85e52e065b58579902ccd35da4ab0f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40900794. Agents can read the archived copy with the MCP tool read_document.